Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,852 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depression, Major Depressive Disorder
Interventions
Clinical decision support tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Major Depressive Disorder, MDD, Depression, Major Depressive Episode
Interventions
transcranial direct current stimulation (tDCS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300, Placebo
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Chino, California • Garden Grove, California • Glendale, California + 25 more
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Conditions
Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Conditions
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Interventions
Perampanel 6 MG, Ketamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Phase 1Phase 2 Interventional Results available

Technology Enhanced Family Treatment

NCT03913013
Conditions
Mood Disorders, Bipolar Disorder, Major Depression
Interventions
Family-Focused Treatment with MCC App
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Suicide Risk, Major Depressive Disorder (MDD)
Interventions
Suvorexant (dual orexin receptor antagonist)
Drug
Lead sponsor
Marianne Goodman
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Depressive Disorder, Major
Interventions
AGN-241751, Placebo
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
Fayetteville, Arkansas • Cerritos, California • Encino, California + 20 more
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Chino, California • Los Angeles, California • Stanford, California + 11 more
Completed Not applicable Interventional Accepts healthy volunteers

Postpartum Video Education

NCT05159726
Conditions
Postpartum Hemorrhage, Postpartum Preeclampsia, Postpartum Sepsis, Postpartum Depression, Patient Empowerment, Patient Education, Postpartum Care
Interventions
Video Education
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 and Digoxin in Healthy Subjects

NCT01266590
Conditions
Major Depressive Disorder
Interventions
LY2216684, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine only
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Postpartum Depression
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, New York
Conditions
Depressive Disorder, Major, Cannabis Abuse
Interventions
Fluoxetine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 25 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Opioid Use Disorder
Interventions
INDV-2000, Placebo
Drug · Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
35
States / cities
Hamilton, Alabama • Phoenix, Arizona • Oceanside, California + 29 more
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Results available

Propranolol for Challenging Behaviors in Autism

NCT04047355
Conditions
Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior, Challenging Behavior
Interventions
Propranolol
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
12 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran, Quetiapine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Alpharetta, Georgia
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana